Top Banner
Antiviral therapy E.McNamara
30

Antiviral therapy

Jan 17, 2016

Download

Documents

Colton

Antiviral therapy. E.McNamara. Challenges. Virus parasitize host cells Target the virus specifically Latency, quiescent phase Is treatment necessary? Efficacy of Rx. Current agents. Exploit viral : host replication Target viral DNA polymerases Accumulate in viral infected cells - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Antiviral therapy

Antiviral therapy

E.McNamara

Page 2: Antiviral therapy

Challenges

• Virus parasitize host cells

• Target the virus specifically

• Latency, quiescent phase

• Is treatment necessary?

• Efficacy of Rx.

Page 3: Antiviral therapy

Current agents

• Exploit viral : host replication

• Target viral DNA polymerases

• Accumulate in viral infected cells

• Activated by virus encoded enzymes

• Dose related toxicity

Page 4: Antiviral therapy

Acyclovir

• Nucleoside analogue

• Inhibits viral DNA polymerase

• Stops replicating viral DNA chains

• Excreted via renal

• Serum half life 2-3 hrs

• Good tissue distribution

• Activated by HSV-TK to triphosphate form

Page 5: Antiviral therapy

Acyclovir toxicities

• CNS,– Confusion, seizures, coma.– Highest risk

• Renal impairment

• Old age

• Prior mental disability

• Potential teratogenicity

• Resistance

Page 6: Antiviral therapy

Acyclovir, uses

• In-vitro– HSV

– VZV

– EBV

– CMV

• In-vivo– HSV

– VZV

Page 7: Antiviral therapy

Famciclovir

• Nucleotide analogue

• Similar spectrum to acyclovir

• Similar mode of action

• Inactive prodrug of penciclovir

• Activated by viral-TK to penciclovir

Page 8: Antiviral therapy

Famciclovir cont.

• Greater bioavailability

• Prolonged intracellular half-life

• TID dosing

Page 9: Antiviral therapy

Famciclovir toxicities

• No major S/E

• Potentially teratogenic

• Potential male infertility

• Levels increased by probenecid

• May increase digoxin levels

Page 10: Antiviral therapy

Valaciclovir

• Valyl ester of acyclovir

• P.O. metabolised to acyclovir

• Plasma levels equivalent to IV acyclovir

• Sustitute for IV acyclovir

• Bioavailability dependant on GIT and hepatic function

Page 11: Antiviral therapy

Valaciclovir

• Toxicities similar to acyclovir

• TTP in immunocompromised on prolonged Rx.

Page 12: Antiviral therapy

Penciclovir

• Nucleoside analogue

• Similar activity to acyclovir

• Topical, Herpes labialis.

Page 13: Antiviral therapy

Herpes infection Rx.

• Improved PO bioavailability• Different mode of action-resistance• Improved efficacy• Type,

– Primary– Secondary/reactivation– Suppressive Rx.

• Vaccines and immunomodulators

Page 14: Antiviral therapy

Herpes Rx.

• HSV– Herpes labialis– Genital herpes– Encephalitis– Immunocompromised

• VZV• H.zoster• EBV

Page 15: Antiviral therapy

Gangciclovir

• Competively inhibits viral DNA polymerase

• Incoporates into viral DNA, chain terminator

• Major agent for CMV

• Accumulates in CMV infected cells

• Excreted renally

• Crosses Blood Brain Barrior

Page 16: Antiviral therapy

Gangciclovir, toxicity

• Haematologic/bone marrow– Neutropaenia– Thrombocytopaenia– Interacts with cytotoxic drugs

• Renal impairment

• Carcinogenic

• Potentiated by probenecid

Page 17: Antiviral therapy

Foscarnet

• Binds viral DNA polymerase and RT.

• Active v Herpes viruses

• Not curative

• Excreted renally

• Variable half-life

• Impairs biochem.– Monitor u/e, creatinine

Page 18: Antiviral therapy

Fomivirsen

• Active v CMV

• Inactivates CMV mRNA

• Local, no systemic anti-CMV Rx.

• Substitute for CMV retinitis Rx.

• Intra-vitreal injections

• S/E, intraocular pressure, retinal toxicity

Page 19: Antiviral therapy

CMV management

• Disseminated disease– Gangciclovir/Foscarnet/– CMV-Iggs, pneumonitis BMT

• Prophylaxis/preemptive in Tx.– Gangciclovir/acyclovir/valaciclovir

• Retinitis– Formiversin/gangciclovir -local

Page 20: Antiviral therapy

Amantadine

• Inhibits Influ-A uncoating on host cell entry• Early Rx. Within 48hrs of symptoms• Prophylaxis of unimmunised high risk• Combined with vaccine until immunity develops• Renal excretion• Rapid resistance• S/E, CNS- dissyness, seizures

Page 21: Antiviral therapy

Rimantadine

• Structural analogue of amantadine

• Fewer CNS S/E

Page 22: Antiviral therapy

Ribavirin

• Synthetic nucleoside

• Interferes with viral RNA transcription

• Acts on RNA viruses– RSV, HCV– Measles– Lassa fever– Hantaviruses

Page 23: Antiviral therapy

Ribavirin uses

• Ribavirin + alpha-interferon for– Chronic HCV– Monitor Hb + WCC

• Aerosol route for RSV, infants

• IV for lassa/hanta

Page 24: Antiviral therapy

Ribavirin toxicities

• Potentially teratogenic

• C.I. For 6 months pre-pregnancy

• Anaemia

• Exacerbation of COPD via aerosol

Page 25: Antiviral therapy

Interferons

• Natural glycopeptides• Induced by viruses (dsRNA)• Affect

– Antiviral

– Antitumour

– Immunomodulators

• Action, induce cellular enzymes to stop protein synthesis and activate RNA degradation

Page 26: Antiviral therapy

Interferons, types

• Alpha-interferon, B-lymphocytes

• Beta-interferon, fibroblasts

• Gamma-interferon, T-lymphocytes

• Recombinant– Interferon alfacon-1– Interferon alfacon-2

Page 27: Antiviral therapy

Interferons, uses

• Routes, SC, IM, intralesional

• Chronic HCV

• Condyloma acuminata-intralesional

• Chronic HBV, remission

Page 28: Antiviral therapy

Interferons, toxicities

• Flu-like symptoms

• Alopecia

• Exac. Psoriasis

• Depression

• Retinal haemorrhages, rare

Page 29: Antiviral therapy

Viral hepatitis

• HAV, – Supportive– Prophylaxis with HAV IGg– Vaccine

• HBV– Interferon-alpha– Lamivudine– Vaccine /HBIG

• HCV– Interferon +ribavirin, Tx.

Page 30: Antiviral therapy

New agents

• Oseltramavir – PO

• Zanamivir – topical

– Neuraminidase inhibitors– Active v Influenza A+B

• Sorivudine-VZV+HSV1, 2 step activation

• Cidofovir, resistant HSV and CMV